{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:24Z","timestamp":1791332304909,"version":"4.3.1"},"publisher-location":"Cham","reference-count":303,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030753924","type":"print"},{"value":"9783030753931","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/7854_2020_204","type":"book-chapter","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T19:03:23Z","timestamp":1615316603000},"page":"331-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pharmacotherapeutic Strategies and New Targets in OCD"],"prefix":"10.1007","author":[{"given":"Christopher","family":"Pittenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"issue":"1","key":"204_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","volume":"29","author":"E Aboujaoude","year":"2009","unstructured":"Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29(1):51\u201355","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"204_CR2","first-page":"157","volume":"32","author":"DL Ackerman","year":"1996","unstructured":"Ackerman DL, Greenland S, Bystritsky A (1996a) Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol Bull 32(1):157\u2013165","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"204_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00004714-199608000-00009","volume":"16","author":"DL Ackerman","year":"1996","unstructured":"Ackerman DL, Greenland S, Bystritsky A, Katz RJ (1996b) Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder. J Clin Psychopharmacol 16(4):324\u2013328","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"204_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00004714-199806000-00002","volume":"18","author":"DL Ackerman","year":"1998","unstructured":"Ackerman DL, Greenland S, Bystritsky A (1998) Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 18(3):185\u2013192","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"204_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S1461145705005055","volume":"8","author":"KH Adams","year":"2005","unstructured":"Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM (2005) Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 8(3):391\u2013401","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"204_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JCP.0000000000000659","volume":"37","author":"TG Adams","year":"2017","unstructured":"Adams TG, Bloch MH, Pittenger C (2017) Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 37(2):269\u2013271","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"204_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","volume":"32","author":"H Afshar","year":"2012","unstructured":"Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H (2012) N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 32(6):797\u2013803","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"204_CR8","first-page":"976","volume":"19","author":"H Afshar","year":"2014","unstructured":"Afshar H, Akuchekian S, Mahaky B, Zarean E (2014) Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Res Med Sci 19(10):976\u2013981","journal-title":"J Res Med Sci"},{"key":"204_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroscience.2015.11.009","volume":"321","author":"SE Ahmari","year":"2016","unstructured":"Ahmari SE (2016) Using mice to model obsessive compulsive disorder: from genes to circuits. Neuroscience 321:121\u2013137","journal-title":"Neuroscience"},{"issue":"8","key":"204_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/da.22367","volume":"32","author":"SE Ahmari","year":"2015","unstructured":"Ahmari SE, Dougherty DD (2015) Dissecting OCD circuits: from animal models to targeted treatments. Depress Anxiety 32(8):550\u2013562","journal-title":"Depress Anxiety"},{"issue":"10","key":"204_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archpsyc.1994.03950100042004","volume":"51","author":"M Altemus","year":"1994","unstructured":"Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51(10):794\u2013803","journal-title":"Arch Gen Psychiatry"},{"issue":"5903","key":"204_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.1156409","volume":"322","author":"D Altshuler","year":"2008","unstructured":"Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322(5903):881\u2013888","journal-title":"Science"},{"key":"204_CR13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association. and American Psychiatric Association. DSM-5 Task Force","year":"2013","unstructured":"American Psychiatric Association. and American Psychiatric Association. DSM-5 Task Force (2013) Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Washington"},{"key":"204_CR14","doi-asserted-by":"crossref","unstructured":"Andrade C (2019) Augmentation with memantine in obsessive-compulsive disorder. J Clin Psychiatry 80(6)","DOI":"10.4088\/JCP.19f13163"},{"issue":"8","key":"204_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.biopsych.2013.10.021","volume":"75","author":"A Anticevic","year":"2014","unstructured":"Anticevic A, Hu S, Zhang S, Savic A, Billingslea E, Wasylink S, Repovs G, Cole MW, Bednarski S, Krystal JH, Bloch MH, Li CS, Pittenger C (2014) Global resting-state functional magnetic resonance imaging analysis identifies frontal cortex, striatal, and cerebellar dysconnectivity in obsessive-compulsive disorder. Biol Psychiatry 75(8):595\u2013605","journal-title":"Biol Psychiatry"},{"key":"204_CR16","volume":"2013","author":"M Arrojo-Romero","year":"2013","unstructured":"Arrojo-Romero M, Tajes Alonso M, de Leon J (2013) Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry 2013:612459","journal-title":"Case Rep Psychiatry"},{"issue":"1","key":"204_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/JCP.0000000000000989","volume":"39","author":"S Balachander","year":"2019","unstructured":"Balachander S, Kodancha PG, Arumugham SS, Sekharan JT, Narayanaswamy JC, Reddy YCJ (2019) Effectiveness of venlafaxine in selective serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: experience from a specialty Clinic in India. J Clin Psychopharmacol 39(1):82\u201385","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"204_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881105059253","volume":"19","author":"DS Baldwin","year":"2005","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, P. British Association for (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19(6):567\u2013596","journal-title":"J Psychopharmacol"},{"issue":"4","key":"204_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archpsyc.1994.03950040053007","volume":"51","author":"LC Barr","year":"1994","unstructured":"Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, Price LH (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51(4):309\u2013317","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"204_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0006-3223(91)90166-J","volume":"30","author":"B Bastani","year":"1991","unstructured":"Bastani B, Arora RC, Meltzer HY (1991) Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry 30(2):131\u2013139","journal-title":"Biol Psychiatry"},{"issue":"Suppl","key":"204_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1192\/S0007125000297857","volume":"35","author":"HG Baumgarten","year":"1998","unstructured":"Baumgarten HG, Grozdanovic Z (1998) Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry 35(Suppl):13\u201320","journal-title":"Br J Psychiatry"},{"issue":"8","key":"204_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajmg.b.32269","volume":"165B","author":"J Bergin","year":"2014","unstructured":"Bergin J, Verhulst B, Aggen SH, Neale MC, Kendler KS, Bienvenu OJ, Hettema JM (2014) Obsessive compulsive symptom dimensions and neuroticism: an examination of shared genetic and environmental risk. Am J Med Genet B Neuropsychiatr Genet 165B(8):647\u2013653","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"5","key":"204_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","volume":"72","author":"HA Berlin","year":"2011","unstructured":"Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E (2011) Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 72(5):716\u2013721","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"204_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351\u2013354","journal-title":"Biol Psychiatry"},{"issue":"9","key":"204_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.biopsych.2005.08.023","volume":"59","author":"A Berney","year":"2006","unstructured":"Berney A, Sookman D, Leyton M, Young SN, Benkelfat C (2006) Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry 59(9):853\u2013857","journal-title":"Biol Psychiatry"},{"issue":"12","key":"204_CR27","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/npp.2009.77","volume":"34","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK (2009) Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 34(12):2489\u20132496","journal-title":"Neuropsychopharmacology"},{"key":"204_CR193","unstructured":"Biohaven Pharmaceuticals (2020). https:\/\/www.biohavenpharma.com\/investors\/news-events\/press-releases\/06-24-2020"},{"key":"204_CR28","unstructured":"BioSpace (2012) Transcept Pharmaceuticals, Inc.\u2019s drug for obsessive compulsive Disroder fails trial. https:\/\/www.biospace.com\/article\/releases\/transcept-pharmaceuticals-inc-s-drug-for-obsessive-compulsive-disorder-fails-trial\u2212\/. Accessed 22 May 2020"},{"issue":"4","key":"204_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11920-008-0052-z","volume":"10","author":"MH Bloch","year":"2008","unstructured":"Bloch MH (2008) Emerging treatments for Tourette's disorder. Curr Psychiatry Rep 10(4):323\u2013330","journal-title":"Curr Psychiatry Rep"},{"issue":"7","key":"204_CR30","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"MH Bloch","year":"2006","unstructured":"Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11(7):622\u2013632","journal-title":"Mol Psychiatry"},{"issue":"12","key":"204_CR31","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1176\/appi.ajp.2008.08020320","volume":"165","author":"MH Bloch","year":"2008","unstructured":"Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF (2008a) Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 165(12):1532\u20131542","journal-title":"Am J Psychiatry"},{"issue":"6","key":"204_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/ajmg.b.30699","volume":"147B","author":"MH Bloch","year":"2008","unstructured":"Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF (2008b) Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet 147B(6):850\u2013858","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"8","key":"204_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/mp.2009.50","volume":"15","author":"MH Bloch","year":"2010","unstructured":"Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010) Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 15(8):850\u2013855","journal-title":"Mol Psychiatry"},{"issue":"11","key":"204_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","volume":"72","author":"MH Bloch","year":"2012","unstructured":"Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C (2012) Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 72(11):964\u2013970","journal-title":"Biol Psychiatry"},{"issue":"9","key":"204_CR35","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/mp.2014.50","volume":"19","author":"MH Bloch","year":"2014","unstructured":"Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF (2014) Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry 19(9):1025\u20131030","journal-title":"Mol Psychiatry"},{"key":"204_CR36","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"CL Boisseau","year":"2017","unstructured":"Boisseau CL, Schhwartzman CM, Rasmussen SA (2017) Quality of life and psychosocial functioning in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"key":"204_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jneumeth.2017.02.007","volume":"292","author":"M Bortolato","year":"2017","unstructured":"Bortolato M, Pittenger C (2017) Modeling tics in rodents: conceptual challenges and paths forward. J Neurosci Methods 292:12\u201319","journal-title":"J Neurosci Methods"},{"issue":"1","key":"204_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s002130000529","volume":"152","author":"ML Boshuisen","year":"2000","unstructured":"Boshuisen ML, den Boer JA (2000) Zolmitriptan (a 5-HT1B\/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology 152(1):74\u201379","journal-title":"Psychopharmacology"},{"issue":"1","key":"204_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/pgs.11.133","volume":"13","author":"EJ Brandl","year":"2012","unstructured":"Brandl EJ, Muller DJ, Richter MA (2012) Pharmacogenetics of obsessive-compulsive disorders. Pharmacogenomics 13(1):71\u201381","journal-title":"Pharmacogenomics"},{"issue":"2","key":"204_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/tpj.2013.12","volume":"14","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA (2014) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 14(2):176\u2013181","journal-title":"Pharmacogenomics J"},{"key":"204_CR41","volume-title":"Obsessive-copulsive disorder: phenomenology, pathophysiology, and treatment","author":"BP Brennan","year":"2017","unstructured":"Brennan BP, Rauch SL (2017) A review and synthesis of functional neuroimaging studies of obsessive-compulsive disorder. In: Pittenger C (ed) Obsessive-copulsive disorder: phenomenology, pathophysiology, and treatment. Oxford Univeristy Press, New York"},{"issue":"1","key":"204_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.biopsych.2012.06.023","volume":"73","author":"BP Brennan","year":"2013","unstructured":"Brennan BP, Rauch SL, Jensen JE, Pope HG Jr (2013) A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry 73(1):24\u201331","journal-title":"Biol Psychiatry"},{"issue":"1","key":"204_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0925-4927(98)00041-9","volume":"84","author":"AL Brody","year":"1998","unstructured":"Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr (1998) FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 84(1):1\u20136","journal-title":"Psychiatry Res"},{"issue":"11","key":"204_CR44","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/0269881111431751","volume":"26","author":"A Bruno","year":"2012","unstructured":"Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR (2012) Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26(11):1456\u20131462","journal-title":"J Psychopharmacol"},{"issue":"3","key":"204_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173660","volume":"12","author":"PC Burkner","year":"2017","unstructured":"Burkner PC, Bittner N, Holling H, Buhlmann U (2017) D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis. PLoS One 12(3):e0173660","journal-title":"PLoS One"},{"issue":"1","key":"204_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00213-013-3137-2","volume":"230","author":"J Cai","year":"2013","unstructured":"Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, Yu S, Fang Y, Zhang C (2013) Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology 230(1):49\u201355","journal-title":"Psychopharmacology"},{"key":"204_CR47","doi-asserted-by":"crossref","unstructured":"Cappi C, Oliphant ME, Peter Z, Zai G, do Rosario MC, Sullivan CAW, Gupta AR, Hoffman EJ, Virdee M, Olfson E, Abdallah SB, Willsey AJ, Shavitt RG, Miguel EC, Kennedy JL, Richter MA, Fernandez TV (2019) De novo damaging DNA coding mutations are associated with obsessive-compulsive disorder and overlap with Tourette's disorder and autism. Biol Psychiatry","DOI":"10.1016\/j.biopsych.2019.09.029"},{"issue":"11","key":"204_CR48","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1176\/appi.ajp.2019.18101180","volume":"176","author":"L Carmi","year":"2019","unstructured":"Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J (2019) Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry 176(11):931\u2013938","journal-title":"Am J Psychiatry"},{"issue":"5631","key":"204_CR49","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.1083968","volume":"301","author":"A Caspi","year":"2003","unstructured":"Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386\u2013389","journal-title":"Science"},{"issue":"1","key":"204_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuron.2013.10.052","volume":"81","author":"L Castellan Baldan","year":"2014","unstructured":"Castellan Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C (2014) Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 81(1):77\u201390","journal-title":"Neuron"},{"issue":"2","key":"204_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000049282","volume":"34","author":"F Catapano","year":"2001","unstructured":"Catapano F, Sperandeo R, Perris F, Lanzaro M, Maj M (2001) Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 34(2):62\u201368","journal-title":"Psychopathology"},{"issue":"1","key":"204_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0924-977X(96)00382-3","volume":"7","author":"P Cavedini","year":"1997","unstructured":"Cavedini P, Erzegovesi S, Ronchi P, Bellodi L (1997) Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol 7(1):45\u201349","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"204_CR52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","volume":"30","author":"K Chakrabarty","year":"2005","unstructured":"Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30(9):1735\u20131740","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"204_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/WNF.0000000000000079","volume":"38","author":"YJ Chiou","year":"2015","unstructured":"Chiou YJ, Lin PY, Lee Y (2015) Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report. Clin Neuropharmacol 38(3):114\u2013116","journal-title":"Clin Neuropharmacol"},{"issue":"5672","key":"204_CR54","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1126\/science.1094987","volume":"304","author":"HF Clarke","year":"2004","unstructured":"Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC (2004) Cognitive inflexibility after prefrontal serotonin depletion. Science 304(5672):878\u2013880","journal-title":"Science"},{"issue":"11","key":"204_CR55","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1017\/S0033291710000516","volume":"40","author":"H Clarke","year":"2010","unstructured":"Clarke H, Flint J, Attwood AS, Munafo MR (2010) Association of the 5- HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 40(11):1767\u20131778","journal-title":"Psychol Med"},{"issue":"1","key":"204_CR56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4088\/JCP.v66n0107","volume":"66","author":"KM Connor","year":"2005","unstructured":"Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49\u201351","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"204_CR57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","volume":"58","author":"V Coric","year":"2005","unstructured":"Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58(5):424\u2013428","journal-title":"Biol Psychiatry"},{"issue":"7","key":"204_CR58","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.4088\/JCP.16m11101","volume":"78","author":"DLC Costa","year":"2017","unstructured":"Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG (2017) Randomized, double-blind, placebo-controlled trial of N-Acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 78(7):e766\u2013e773","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"204_CR59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pnpbp.2012.07.002","volume":"39","author":"CC D\u2019Alcante","year":"2012","unstructured":"D\u2019Alcante CC, Diniz JB, Fossaluza V, Batistuzzo MC, Lopes AC, Shavitt RG, Deckersbach T, Malloy-Diniz L, Miguel EC, Hoexter MQ (2012) Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 39(2):310\u2013317","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"11","key":"204_CR60","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jpsychires.2013.07.006","volume":"47","author":"DL da Conceicao Costa","year":"2013","unstructured":"da Conceicao Costa DL, Shavitt RG, Castro Cesar RC, Joaquim MA, Borcato S, Valerio C, Miguel EC, Diniz JB (2013) Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. J Psychiatr Res 47(11):1700\u20131707","journal-title":"J Psychiatr Res"},{"issue":"10","key":"204_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003864","volume":"9","author":"LK Davis","year":"2013","unstructured":"Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, Neale BM, Yang J, Lee SH, Evans P, Barr CL, Bellodi L, Benarroch F, Berrio GB, Bienvenu OJ, Bloch MH, Blom RM, Bruun RD, Budman CL, Camarena B, Campbell D, Cappi C, Cardona Silgado JC, Cath DC, Cavallini MC, Chavira DA, Chouinard S, Conti DV, Cook EH, Coric V, Cullen BA, Deforce D, Delorme R, Dion Y, Edlund CK, Egberts K, Falkai P, Fernandez TV, Gallagher PJ, Garrido H, Geller D, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Haddad S, Heiman GA, Hemmings SM, Hounie AG, Illmann C, Jankovic J, Jenike MA, Kennedy JL, King RA, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Macciardi F, McCracken JT, McGrath LM, Mesa Restrepo SC, Moessner R, Morgan J, Muller H, Murphy DL, Naarden AL, Ochoa WC, Ophoff RA, Osiecki L, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner TJ, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosario MC, Rosenberg D, Rouleau GA, Ruhrmann S, Ruiz-Linares A, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Valencia Duarte AV, Vallada H, Van Nieuwerburgh F, Veenstra-Vanderweele J, Walitza S, Wang Y, Wendland JR, Westenberg HG, Shugart YY, Miguel EC, McMahon W, Wagner M, Nicolini H, Posthuma D, Hanna GL, Heutink P, Denys D, Arnold PD, Oostra BA, Nestadt G, Freimer NB, Pauls DL, Wray NR, Stewart SE, Mathews CA, Knowles JA, Cox NJ, Scharf JM (2013) Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet 9(10):e1003864","journal-title":"PLoS Genet"},{"issue":"6","key":"204_CR62","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41386-018-0302-7","volume":"44","author":"C Delgado-Acevedo","year":"2019","unstructured":"Delgado-Acevedo C, Estay SF, Radke AK, Sengupta A, Escobar AP, Henriquez-Belmar F, Reyes CA, Haro-Acuna V, Utreras E, Sotomayor-Zarate R, Cho A, Wendland JR, Kulkarni AB, Holmes A, Murphy DL, Chavez AE, Moya PR (2019) Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. Neuropsychopharmacology 44(6):1163\u20131173","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"204_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.jcp.0000104905.75206.50","volume":"24","author":"R Delorme","year":"2004","unstructured":"Delorme R, Chabane N, Callebert J, Falissard B, Mouren-Simeoni MC, Rouillon F, Launay JM, Leboyer M (2004) Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. J Clin Psychopharmacol 24(1):18\u201323","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"204_CR64","first-page":"315","volume":"18","author":"D Denys","year":"2003","unstructured":"Denys D, Burger H, van Megen H, de Geus F, Westenberg H (2003) A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 18(6):315\u2013322","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"204_CR65","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.biopsych.2004.01.023","volume":"55","author":"D Denys","year":"2004","unstructured":"Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG (2004a) Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 55(10):1041\u20131045","journal-title":"Biol Psychiatry"},{"issue":"1","key":"204_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4088\/JCP.v65n0106","volume":"65","author":"D Denys","year":"2004","unstructured":"Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004b) A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65(1):37\u201343","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 14","key":"204_CR67","first-page":"11","volume":"65","author":"D Denys","year":"2004","unstructured":"Denys D, Zohar J, Westenberg HG (2004c) The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65(Suppl 14):11\u201317","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"204_CR68","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4088\/JCP.v68n0512","volume":"68","author":"D Denys","year":"2007","unstructured":"Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG (2007) Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68(5):747\u2013753","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"204_CR69","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","volume":"23","author":"D Denys","year":"2013","unstructured":"Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN (2013) Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol 23(11):1423\u20131431","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"204_CR70","first-page":"36","volume":"25","author":"J DeVeaugh-Geiss","year":"1989","unstructured":"DeVeaugh-Geiss J, Landau P, Katz R (1989) Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 25(1):36\u201340","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"204_CR71","first-page":"54","volume":"26","author":"J DeVeaugh-Geiss","year":"1990","unstructured":"DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S (1990) Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 26(1):54\u201359","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"204_CR72","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cell.2017.04.006","volume":"169","author":"MO Dietrich","year":"2017","unstructured":"Dietrich MO, Zimmer MR, Bober J, Horvath TL (2017) Hypothalamic Agrp neurons drive stereotypic behaviors beyond feeding. Cell 169(3):559","journal-title":"Cell"},{"key":"204_CR73","doi-asserted-by":"crossref","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 18(9)","DOI":"10.1093\/ijnp\/pyv047"},{"issue":"18","key":"204_CR74","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","volume":"231","author":"D Ducasse","year":"2014","unstructured":"Ducasse D, Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, Courtet P, Abbar M, Leboyer M, Fond G (2014) D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology 231(18):3765\u20133770","journal-title":"Psychopharmacology"},{"issue":"6","key":"204_CR75","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/comp.2001.27898","volume":"42","author":"JL Eisen","year":"2001","unstructured":"Eisen JL, Rasmussen SA, Phillips KA, Price LH, Davidson J, Lydiard RB, Ninan P, Piggott T (2001) Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 42(6):494\u2013497","journal-title":"Compr Psychiatry"},{"issue":"4","key":"204_CR76","first-page":"268","volume":"30","author":"M El Mansari","year":"2005","unstructured":"El Mansari M, Blier P (2005) Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 30(4):268\u2013274","journal-title":"J Psychiatry Neurosci"},{"issue":"8","key":"204_CR77","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/pcn.12394","volume":"70","author":"S Emamzadehfard","year":"2016","unstructured":"Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2016) Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 70(8):332\u2013341","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"204_CR78","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/00004714-200110000-00006","volume":"21","author":"S Erzegovesi","year":"2001","unstructured":"Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L (2001) Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21(5):488\u2013492","journal-title":"J Clin Psychopharmacol"},{"key":"204_CR79","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fphar.2019.01362","volume":"10","author":"AP Escobar","year":"2019","unstructured":"Escobar AP, Wendland JR, Chavez AE, Moya PR (2019) The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol 10:1362","journal-title":"Front Pharmacol"},{"key":"204_CR80","unstructured":"Excellence, N. I. f. C (2006) Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. https:\/\/www.nice.org.uk\/guidance\/cg31. Accessed 15 Apr 2020"},{"issue":"10","key":"204_CR81","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/archpsyc.55.10.918","volume":"55","author":"BA Fallon","year":"1998","unstructured":"Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF (1998) Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 55(10):918\u2013924","journal-title":"Arch Gen Psychiatry"},{"key":"204_CR82","unstructured":"FDA (2012) FDA drug safety communications: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm. Accessed 20 May 2020"},{"issue":"2","key":"204_CR83","first-page":"119","volume":"26","author":"E Fernandez Cordoba","year":"1967","unstructured":"Fernandez Cordoba E, Lopez-Ibor Alino J (1967) Use of monochlorimipramine in psychiatric patients who are resistant to other therapy. Actas Luso Esp Neurol Psiquiatr 26(2):119\u2013147","journal-title":"Actas Luso Esp Neurol Psiquiatr"},{"key":"204_CR84","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/B978-0-444-64076-5.00049-1","volume":"148","author":"TV Fernandez","year":"2018","unstructured":"Fernandez TV, Leckman JF, Pittenger C (2018) Genetic susceptibility in obsessive-compulsive disorder. Handb Clin Neurol 148:767\u2013781","journal-title":"Handb Clin Neurol"},{"issue":"1\u20133","key":"204_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jad.2006.04.019","volume":"94","author":"YA Ferrao","year":"2006","unstructured":"Ferrao YA, Shavitt RG, Bedin NR, de Mathis ME, Carlos Lopes A, Fontenelle LF, Torres AR, Miguel EC (2006) Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord 94(1\u20133):199\u2013209","journal-title":"J Affect Disord"},{"issue":"1","key":"204_CR86","first-page":"81","volume":"42","author":"JD Feusner","year":"2009","unstructured":"Feusner JD, Kerwin L, Saxena S, Bystritsky A (2009) Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 42(1):81\u201393","journal-title":"Psychopharmacol Bull"},{"key":"204_CR87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145704004675","volume":"8","author":"NA Fineberg","year":"2005","unstructured":"Fineberg NA, Gale T (2005) Evidence-based pharmacological treatments for obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107\u2013129","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"204_CR88","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","volume":"227","author":"NA Fineberg","year":"2015","unstructured":"Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, Stein DJ, Sareen J, Brown A, Sookman D, D. Accreditation Task Force of The Canadian Institute for Obsessive Compulsive (2015) Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res 227(1):114\u2013125","journal-title":"Psychiatry Res"},{"issue":"4","key":"204_CR89","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1176\/jnp.13.4.508","volume":"13","author":"L Fontenelle","year":"2001","unstructured":"Fontenelle L, Marques C, Engelhardt E, Versiani M (2001) Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 13(4):508\u2013510","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"204_CR90","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrc4015","volume":"15","author":"AA Friedman","year":"2015","unstructured":"Friedman AA, Letai A, Fisher DE, Flaherty KT (2015) Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 15(12):747\u2013756","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"204_CR91","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1503\/jpn.160215","volume":"42","author":"MA Fullana","year":"2017","unstructured":"Fullana MA, Zhu X, Alonso P, Cardoner N, Real E, Lopez-Sola C, Segalas C, Subira M, Galfalvy H, Menchon JM, Simpson HB, Marsh R, Soriano-Mas C (2017) Basolateral amygdala-ventromedial prefrontal cortex connectivity predicts cognitive behavioural therapy outcome in adults with obsessive-compulsive disorder. J Psychiatry Neurosci 42(6):378\u2013385","journal-title":"J Psychiatry Neurosci"},{"key":"204_CR92","first-page":"100529","volume":"25","author":"AHA Gadallah","year":"2020","unstructured":"Gadallah AHA, Ebada MA, Gadallah A, Ahmed H, Rashad W, Eid KA, Bahbah E, Alkanj S (2020) Efficacy and safety of N-acetylcysteine as add-on therapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. J OCD Relat Disord 25:100529","journal-title":"J OCD Relat Disord"},{"issue":"2","key":"204_CR93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S (2013) Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 47(2):175\u2013180","journal-title":"J Psychiatr Res"},{"issue":"2","key":"204_CR94","first-page":"134","volume":"12","author":"A Ghanizadeh","year":"2017","unstructured":"Ghanizadeh A, Mohammadi MR, Bahraini S, Keshavarzi Z, Firoozabadi A, Alavi Shoshtari A (2017) Efficacy of N-Acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial. Iran J Psychiatry 12(2):134\u2013141","journal-title":"Iran J Psychiatry"},{"issue":"1","key":"204_CR95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989a) Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 46(1):36\u201344","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"204_CR96","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989b) The Yale-Brown obsessive compulsive scale. II. Validity. Arch Gen Psychiatry 46(11):1012\u20131016","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"204_CR97","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989c) The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 46(11):1006\u20131011","journal-title":"Arch Gen Psychiatry"},{"key":"204_CR98","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"I Graat","year":"2017","unstructured":"Graat I, Figee M, Denys D (2017) Neurotransmitter dysregulation in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"6","key":"204_CR99","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/npp.2013.343","volume":"39","author":"PJ Grant","year":"2014","unstructured":"Grant PJ, Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA Jr, Swedo SE (2014) 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 39(6):1453\u20131459","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"204_CR100","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","volume":"43","author":"WM Greenberg","year":"2009","unstructured":"Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, Javitt DC (2009) Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res 43(6):664\u2013670","journal-title":"J Psychiatr Res"},{"key":"204_CR101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","volume":"246","author":"D Grillault Laroche","year":"2016","unstructured":"Grillault Laroche D, Gaillard A (2016) Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses. Psychiatry Res 246:119\u2013128","journal-title":"Psychiatry Res"},{"issue":"3","key":"204_CR102","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000079970","volume":"50","author":"R Gross-Isseroff","year":"2004","unstructured":"Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004) Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50(3):200\u2013205","journal-title":"Neuropsychobiology"},{"issue":"8","key":"204_CR103","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","volume":"48","author":"Group, C. C. S","year":"1991","unstructured":"Group, C. C. S (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 48(8):730\u2013738","journal-title":"Arch Gen Psychiatry"},{"key":"204_CR104","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.neuroscience.2016.07.030","volume":"345","author":"P Gruner","year":"2017","unstructured":"Gruner P, Pittenger C (2017) Cognitive inflexibility in obsessive-compulsive disorder. Neuroscience 345:243\u2013255","journal-title":"Neuroscience"},{"issue":"4","key":"204_CR105","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"M Haghighi","year":"2013","unstructured":"Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S (2013) In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology 228(4):633\u2013640","journal-title":"Psychopharmacology"},{"key":"204_CR106","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"RJ Hamblin","year":"2017","unstructured":"Hamblin RJ, Park JM, Wu MS, Storch EA (2017) Variable insight in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"5","key":"204_CR107","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ajmg.10519","volume":"114","author":"GL Hanna","year":"2002","unstructured":"Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, Leventhal BL, Cook EH Jr (2002) Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet 114(5):541\u2013552","journal-title":"Am J Med Genet"},{"issue":"11","key":"204_CR108","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/archgenpsychiatry.2009.152","volume":"66","author":"BJ Harrison","year":"2009","unstructured":"Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, Lopez-Sola M, Hernandez-Ribas R, Deus J, Alonso P, Yucel M, Pantelis C, Menchon JM, Cardoner N (2009) Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry 66(11):1189\u20131200","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"204_CR109","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.biopsych.2012.10.006","volume":"73","author":"BJ Harrison","year":"2013","unstructured":"Harrison BJ, Pujol J, Cardoner N, Deus J, Alonso P, Lopez-Sola M, Contreras-Rodriguez O, Real E, Segalas C, Blanco-Hinojo L, Menchon JM, Soriano-Mas C (2013) Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biol Psychiatry 73(4):321\u2013328","journal-title":"Biol Psychiatry"},{"issue":"10","key":"204_CR110","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","volume":"28","author":"M Hasnain","year":"2014","unstructured":"Hasnain M, Vieweg WV (2014) QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 28(10):887\u2013920","journal-title":"CNS Drugs"},{"issue":"10","key":"204_CR111","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/14737175.2016.1199960","volume":"16","author":"N Hazari","year":"2016","unstructured":"Hazari N, Narayanaswamy JC, Arumugham SS (2016) Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. Expert Rev Neurother 16(10):1175\u20131191","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"204_CR112","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0006-3223(99)00171-7","volume":"47","author":"A Heinz","year":"2000","unstructured":"Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR (2000) A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47(7):643\u2013649","journal-title":"Biol Psychiatry"},{"issue":"2","key":"204_CR113","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0925-4927(03)00091-X","volume":"124","author":"T Hendler","year":"2003","unstructured":"Hendler T, Goshen E, Tzila Zwas S, Sasson Y, Gal G, Zohar J (2003) Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 124(2):87\u2013103","journal-title":"Psychiatry Res"},{"issue":"1","key":"204_CR114","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pscychresns.2005.07.002","volume":"140","author":"S Hesse","year":"2005","unstructured":"Hesse S, Muller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005) Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 140(1):63\u201372","journal-title":"Psychiatry Res"},{"issue":"2","key":"204_CR115","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1176\/appi.ajp.2008.08091427","volume":"166","author":"DM Hezel","year":"2009","unstructured":"Hezel DM, Beattie K, Stewart SE (2009) Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry 166(2):237","journal-title":"Am J Psychiatry"},{"issue":"2","key":"204_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pscychresns.2004.12.003","volume":"138","author":"KL Ho Pian","year":"2005","unstructured":"Ho Pian KL, van Megen HJ, Ramsey NF, Mandl R, van Rijk PP, Wynne HJ, Westenberg HG (2005) Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res 138(2):89\u201397","journal-title":"Psychiatry Res"},{"issue":"7","key":"204_CR117","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.euroneuro.2012.06.014","volume":"23","author":"MQ Hoexter","year":"2013","unstructured":"Hoexter MQ, Dougherty DD, Shavitt RG, D'Alcante CC, Duran FL, Lopes AC, Diniz JB, Batistuzzo MC, Evans KC, Bressan RA, Busatto GF, Miguel EC (2013) Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder. Eur Neuropsychopharmacol 23(7):569\u2013580","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"204_CR118","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/da.22380","volume":"32","author":"MQ Hoexter","year":"2015","unstructured":"Hoexter MQ, Diniz JB, Lopes AC, Batistuzzo MC, Shavitt RG, Dougherty DD, Duran FL, Bressan RA, Busatto GF, Miguel EC, Sato JR (2015) Orbitofrontal thickness as a measure for treatment response prediction in obsessive-compulsive disorder. Depress Anxiety 32(12):900\u2013908","journal-title":"Depress Anxiety"},{"issue":"5","key":"204_CR119","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.euroneuro.2016.02.006","volume":"26","author":"E Hollander","year":"2016","unstructured":"Hollander E, Doernberg E, Shavitt R, Waterman RJ, Soreni N, Veltman DJ, Sahakian BJ, Fineberg NA (2016) The cost and impact of compulsivity: a research perspective. Eur Neuropsychopharmacol 26(5):800\u2013809","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"204_CR120","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1177\/0269881117736916","volume":"31","author":"SD Hood","year":"2017","unstructured":"Hood SD, Broyd A, Robinson H, Lee J, Hudaib AR, Hince DA (2017) Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. J Psychopharmacol 31(12):1615\u20131623","journal-title":"J Psychopharmacol"},{"issue":"4","key":"204_CR121","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/pcn.12139","volume":"68","author":"HJ Hsieh","year":"2014","unstructured":"Hsieh HJ, Lue KH, Tsai HC, Lee CC, Chen SY, Kao PF (2014) L-3,4-Dihydroxy-6-[F-18]fluorophenylalanine positron emission tomography demonstrating dopaminergic system abnormality in the brains of obsessive-compulsive disorder patients. Psychiatry Clin Neurosci 68(4):292\u2013298","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"204_CR122","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0006-3223(00)00956-2","volume":"49","author":"M Humble","year":"2001","unstructured":"Humble M, Bejerot S, Bergqvist PB, Bengtsson F (2001) Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. Biol Psychiatry 49(4):360\u2013368","journal-title":"Biol Psychiatry"},{"issue":"6","key":"204_CR123","first-page":"648","volume":"103","author":"MZ Hussain","year":"1970","unstructured":"Hussain MZ, Ahad A (1970) Treatment of obsessive-compulsive neurosis. Can Med Assoc J 103(6):648","journal-title":"Can Med Assoc J"},{"issue":"2","key":"204_CR124","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0253-7176.155613","volume":"37","author":"A Hussain","year":"2015","unstructured":"Hussain A, Dar MA, Wani RA, Shah MS, Jan MM, Malik YA, Chandel RK, Margoob MA (2015) Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia. Indian J Psychol Med 37(2):154\u2013158","journal-title":"Indian J Psychol Med"},{"issue":"3","key":"204_CR125","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0897190015624862","volume":"30","author":"LMJ Hutton","year":"2017","unstructured":"Hutton LMJ, Cave AJ, St-Jean R, Banh HL (2017) Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract 30(3):353\u2013358","journal-title":"J Pharm Pract"},{"key":"204_CR126","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.brat.2017.08.009","volume":"99","author":"KA Hybel","year":"2017","unstructured":"Hybel KA, Mortensen EL, Lambek R, Hojgaard D, Thomsen PH (2017) Executive function predicts cognitive-behavioral therapy response in childhood obsessive-compulsive disorder. Behav Res Ther 99:11\u201318","journal-title":"Behav Res Ther"},{"issue":"6","key":"204_CR127","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","volume":"40","author":"TR Insel","year":"1983","unstructured":"Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M (1983) Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40(6):605\u2013612","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"204_CR128","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/0006-3223(85)90176-3","volume":"20","author":"TR Insel","year":"1985","unstructured":"Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20(11):1174\u20131188","journal-title":"Biol Psychiatry"},{"key":"204_CR129","doi-asserted-by":"crossref","unstructured":"International Obsessive Compulsive Disorder Foundation Genetics Consortium (IOCDF-GC), C. and OCD Collaborative Genetic Association (OCGAS) (2018) Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Mol Psychiatry 23(5):1181\u20131188","DOI":"10.1038\/mp.2017.154"},{"issue":"5","key":"204_CR130","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.4088\/JCP.14r09758","volume":"77","author":"Y Issari","year":"2016","unstructured":"Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH (2016) Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry 77(5):e605\u2013e611","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"204_CR131","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4088\/JCP.v60n0512d","volume":"60","author":"M Iyo","year":"1999","unstructured":"Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N (1999) Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report. J Clin Psychiatry 60(5):337\u2013338","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"204_CR132","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/1817-1745.199461","volume":"11","author":"S Jhanda","year":"2016","unstructured":"Jhanda S, Singla N, Grover S (2016) Methylphenidate-induced obsessive-compulsive symptoms: a case report and review of literature. J Pediatr Neurosci 11(4):316\u2013318","journal-title":"J Pediatr Neurosci"},{"key":"204_CR133","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR (2019) Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther 197:83\u2013102","journal-title":"Pharmacol Ther"},{"issue":"2","key":"204_CR134","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pbb.2011.01.009","volume":"99","author":"GB Kaplan","year":"2011","unstructured":"Kaplan GB, Moore KA (2011) The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 99(2):217\u2013228","journal-title":"Pharmacol Biochem Behav"},{"key":"204_CR135","doi-asserted-by":"crossref","unstructured":"Karameh WK, Khani M (2015) Intravenous clomipramine for treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 19(2)","DOI":"10.1093\/ijnp\/pyv084"},{"key":"204_CR136","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/NDT.S211703","volume":"16","author":"S Karthik","year":"2020","unstructured":"Karthik S, Sharma LP, Narayanaswamy JC (2020) Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat 16:1003\u20131013","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"204_CR137","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0006-3223(90)90408-T","volume":"28","author":"RJ Katz","year":"1990","unstructured":"Katz RJ, DeVeaugh-Geiss J, Landau P (1990) Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28(5):401\u2013414","journal-title":"Biol Psychiatry"},{"issue":"3","key":"204_CR138","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21(3):169\u2013184","journal-title":"Int J Methods Psychiatr Res"},{"issue":"2","key":"204_CR139","first-page":"104","volume":"11","author":"M Khalkhali","year":"2016","unstructured":"Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A (2016) Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry 11(2):104\u2013114","journal-title":"Iran J Psychiatry"},{"issue":"12","key":"204_CR140","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00259-003-1245-7","volume":"30","author":"CH Kim","year":"2003","unstructured":"Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS (2003) Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging 30(12):1637\u20131643","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"204_CR141","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41386-019-0436-2","volume":"44","author":"M Kim","year":"2019","unstructured":"Kim M, Kwak S, Yoon YB, Kwak YB, Kim T, Cho KIK, Lee TY, Kwon JS (2019) Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Neuropsychopharmacology 44(12):2073\u20132081","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"204_CR142","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0893-133X(02)00377-9","volume":"27","author":"S Koch","year":"2002","unstructured":"Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002) R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27(6):949\u2013959","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"204_CR143","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0924-977X(01)00082-7","volume":"11","author":"LM Koran","year":"2001","unstructured":"Koran LM, Pallanti S, Quercioli L (2001) Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 11(2):169\u2013172","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"204_CR144","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4088\/JCP.v66n0415","volume":"66","author":"LM Koran","year":"2005","unstructured":"Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005) Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 66(4):515\u2013520","journal-title":"J Clin Psychiatry"},{"issue":"7 Suppl","key":"204_CR145","first-page":"5","volume":"164","author":"LM Koran","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, A. American Psychiatric (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(7 Suppl):5\u201353","journal-title":"Am J Psychiatry"},{"issue":"11","key":"204_CR146","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.4088\/JCP.08m04605","volume":"70","author":"LM Koran","year":"2009","unstructured":"Koran LM, Aboujaoude E, Gamel NN (2009) Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 70(11):1530\u20131535","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"204_CR147","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.pnpbp.2007.08.032","volume":"32","author":"S Korff","year":"2008","unstructured":"Korff S, Stein DJ, Harvey BH (2008) Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 32(2):348\u2013355","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"204_CR148","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00004583-199802000-00001","volume":"37","author":"S Kouris","year":"1998","unstructured":"Kouris S (1998) Methylphenidate-induced obsessive-compulsiveness. J Am Acad Child Adolesc Psychiatry 37(2):135","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"13","key":"204_CR149","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","volume":"234","author":"R Kraehenmann","year":"2017","unstructured":"Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX (2017) Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology 234(13):2031\u20132046","journal-title":"Psychopharmacology"},{"issue":"5","key":"204_CR150","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS (2019) Ketamine: a paradigm shift for depression research and treatment. Neuron 101(5):774\u2013778","journal-title":"Neuron"},{"issue":"2\u20133","key":"204_CR151","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000115778","volume":"56","author":"AK Kulz","year":"2007","unstructured":"Kulz AK, Meinzer S, Kopasz M, Voderholzer U (2007) Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology 56(2\u20133):127\u2013131","journal-title":"Neuropsychobiology"},{"issue":"3","key":"204_CR152","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/j.1440-1614.2000.0751c.x","volume":"34","author":"TC Kumar","year":"2000","unstructured":"Kumar TC, Khanna S (2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34(3):527\u2013528","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"204_CR153","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","volume":"184","author":"DL Lafleur","year":"2006","unstructured":"Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V (2006) N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 184(2):254\u2013256","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"204_CR154","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jad.2009.06.010","volume":"121","author":"A Landeros-Weisenberger","year":"2010","unstructured":"Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V (2010) Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord 121(1\u20132):175\u2013179","journal-title":"J Affect Disord"},{"issue":"1","key":"204_CR155","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.npp.1380241","volume":"12","author":"JF Leckman","year":"1995","unstructured":"Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL et al (1995) Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12(1):73\u201386","journal-title":"Neuropsychopharmacology"},{"issue":"5292","key":"204_CR156","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","volume":"274","author":"KP Lesch","year":"1996","unstructured":"Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527\u20131531","journal-title":"Science"},{"key":"204_CR157","unstructured":"Lochner C et al (2001) Venlafaxine in obsessive compulsive disorder. In: Fifth Internatonal obsessive compulsive disorder conference, Sardinia, Italy"},{"issue":"3","key":"204_CR158","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","volume":"27","author":"L Lykouras","year":"2003","unstructured":"Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003) Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuro-Psychopharmacol Biol Psychiatry 27(3):333\u2013346","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"204_CR159","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0165-1781(92)90037-4","volume":"42","author":"D Marazziti","year":"1992","unstructured":"Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB (1992) Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 42(1):41\u201351","journal-title":"Psychiatry Res"},{"issue":"4","key":"204_CR160","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000119308","volume":"34","author":"D Marazziti","year":"1996","unstructured":"Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, Presta S, Lucacchini A, Cassano GB (1996) Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology 34(4):184\u2013187","journal-title":"Neuropsychobiology"},{"issue":"6","key":"204_CR161","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-2007-979501","volume":"30","author":"D Marazziti","year":"1997","unstructured":"Marazziti D, Pfanner C, Palego L, Gemignani A, Milanfranchi A, Ravagli S, Lensi P, Presta S, Cassano GB (1997) Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine. Pharmacopsychiatry 30(6):245\u2013249","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"204_CR162","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0165-1781(99)00102-X","volume":"89","author":"D Marazziti","year":"1999","unstructured":"Marazziti D, Dell'Osso L, Presta S, Pfanner C, Rossi A, Masala I, Baroni S, Giannaccini G, Lucacchini A, Cassano GB (1999) Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry Res 89(3):223\u2013228","journal-title":"Psychiatry Res"},{"issue":"7","key":"204_CR163","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/1570159X15666170320104237","volume":"15","author":"Z Marinova","year":"2017","unstructured":"Marinova Z, Chuang DM, Fineberg N (2017) Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol 15(7):977\u2013995","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"204_CR164","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clineuro.2008.10.001","volume":"111","author":"M Markianos","year":"2009","unstructured":"Markianos M, Lafazanos S, Koutsis G, Sfagos C, Seretis A (2009) CSF neurotransmitter metabolites and neuropsychiatric symptomatology in patients with normal pressure hydrocephalus. Clin Neurol Neurosurg 111(3):231\u2013234","journal-title":"Clin Neurol Neurosurg"},{"key":"204_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.136.1.1","volume":"136","author":"IM Marks","year":"1980","unstructured":"Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 136:1\u201325","journal-title":"Br J Psychiatry"},{"issue":"12","key":"204_CR166","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.mp.4002015","volume":"12","author":"SS Marroni","year":"2007","unstructured":"Marroni SS, Nakano FN, Gati CD, Oliveira JA, Antunes-Rodrigues J, Garcia-Cairasco N (2007) Neuroanatomical and cellular substrates of hypergrooming induced by microinjection of oxytocin in central nucleus of amygdala, an experimental model of compulsive behavior. Mol Psychiatry 12(12):1103\u20131117","journal-title":"Mol Psychiatry"},{"issue":"5","key":"204_CR167","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000064812","volume":"71","author":"D Mataix-Cols","year":"2002","unstructured":"Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L (2002) Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosom 71(5):255\u2013262","journal-title":"Psychother Psychosom"},{"issue":"5","key":"204_CR168","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"D Mataix-Cols","year":"2017","unstructured":"Mataix-Cols D, Fernandez de la Cruz L, Monzani B, Rosenfield D, Andersson E, Perez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Strohle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Ruck C, D. C. S. A. C. the, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner C, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiat 74(5):501\u2013510","journal-title":"JAMA Psychiat"},{"issue":"3","key":"204_CR169","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/mp.2014.43","volume":"20","author":"M Mattheisen","year":"2015","unstructured":"Mattheisen M, Samuels JF, Wang Y, Greenberg BD, Fyer AJ, McCracken JT, Geller DA, Murphy DL, Knowles JA, Grados MA, Riddle MA, Rasmussen SA, McLaughlin NC, Nurmi EL, Askland KD, Qin HD, Cullen BA, Piacentini J, Pauls DL, Bienvenu OJ, Stewart SE, Liang KY, Goes FS, Maher B, Pulver AE, Shugart YY, Valle D, Lange C, Nestadt G (2015) Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry 20(3):337\u2013344","journal-title":"Mol Psychiatry"},{"issue":"5","key":"204_CR170","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/00004714-199310000-00008","volume":"13","author":"CJ McDougle","year":"1993","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH (1993) The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13(5):354\u2013358","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"204_CR171","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"CJ McDougle","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51(4):302\u2013308","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"204_CR172","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","volume":"152","author":"CJ McDougle","year":"1995","unstructured":"McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH (1995) Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152(12):1812\u20131814","journal-title":"Am J Psychiatry"},{"issue":"1","key":"204_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0306-4530(98)00046-8","volume":"24","author":"CJ McDougle","year":"1999","unstructured":"McDougle CJ, Barr LC, Goodman WK, Price LH (1999) Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24(1):1\u201324","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"204_CR174","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57(8):794\u2013801","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"204_CR175","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0043-120268","volume":"51","author":"A Modarresi","year":"2018","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L (2018) Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry 51(6):263\u2013269","journal-title":"Pharmacopsychiatry"},{"key":"204_CR176","doi-asserted-by":"publisher","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","volume":"282","author":"A Modarresi","year":"2019","unstructured":"Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR (2019) A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res 282:112602","journal-title":"Psychiatry Res"},{"issue":"2","key":"204_CR177","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","volume":"3","author":"SA Montgomery","year":"1993","unstructured":"Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3(2):143\u2013152","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"204_CR178","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735\u20131740","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"204_CR179","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/JCP.0000000000000592","volume":"36","author":"A Mowla","year":"2016","unstructured":"Mowla A, Boostani S, Dastgheib SA (2016) Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial. J Clin Psychopharmacol 36(6):720\u2013723","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"204_CR180","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/cap.2015.0083","volume":"26","author":"A Naguy","year":"2016","unstructured":"Naguy A, Alamiri B, Al-Khadhari S, Francis K (2016) Lamotrigine augmentation in treatment-resistant pediatric obsessive-compulsive disorder with a 16 month follow-up. J Child Adolesc Psychopharmacol 26(8):769\u2013772","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"204_CR248","unstructured":"NHS (2011) Citalopram and escitalopram: QT interval prolongation. Drug Saf Update 5(5):A1"},{"issue":"1","key":"204_CR181","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1515\/revneuro-2015-0014","volume":"27","author":"S Nikolaus","year":"2016","unstructured":"Nikolaus S, Muller HW, Hautzel H (2016) Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders--a comparative analysis of in vivo imaging findings. Rev Neurosci 27(1):27\u201359","journal-title":"Rev Neurosci"},{"key":"204_CR182","unstructured":"NIMH (2020). https:\/\/www.nimh.nih.gov\/about\/strategic-planning-reports\/goal-3-strive-for-prevention-and-cures.shtml. Accessed 1 July 2020"},{"issue":"1","key":"204_CR183","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1073191115601207","volume":"24","author":"BO Olatunji","year":"2017","unstructured":"Olatunji BO, Ebesutani C, Abramowitz JS (2017) Examination of a Bifactor model of obsessive-compulsive symptom dimensions. Assessment 24(1):45\u201359","journal-title":"Assessment"},{"issue":"1\u20133","key":"204_CR184","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jad.2008.06.020","volume":"114","author":"JS Olver","year":"2009","unstructured":"Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR (2009) Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord 114(1\u20133):321\u2013326","journal-title":"J Affect Disord"},{"issue":"1","key":"204_CR185","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pscychresns.2010.04.004","volume":"183","author":"JS Olver","year":"2010","unstructured":"Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott AM, Norman TR (2010) Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder. Psychiatry Res 183(1):85\u201388","journal-title":"Psychiatry Res"},{"issue":"12","key":"204_CR186","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/npp.2017.77","volume":"42","author":"J O'Neill","year":"2017","unstructured":"O'Neill J, Piacentini J, Chang S, Ly R, Lai TM, Armstrong CC, Bergman L, Rozenman M, Peris T, Vreeland A, Mudgway R, Levitt JG, Salamon N, Posse S, Hellemann GS, Alger JR, McCracken JT, Nurmi EL (2017) Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology 42(12):2414\u20132422","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"204_CR187","first-page":"167","volume":"103","author":"JB O'Regan","year":"1970","unstructured":"O'Regan JB (1970) Treatment of obsessive--compulsive neurosis with haloperidol. Can Med Assoc J 103(2):167\u2013168","journal-title":"Can Med Assoc J"},{"issue":"9","key":"204_CR188","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4088\/JCP.v63n0908","volume":"63","author":"S Pallanti","year":"2002","unstructured":"Pallanti S, Quercioli L, Koran LM (2002) Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63(9):796\u2013801","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"204_CR189","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","volume":"65","author":"S Pallanti","year":"2004","unstructured":"Pallanti S, Quercioli L, Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65(10):1394\u20131399","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"204_CR190","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jcpt.12370","volume":"41","author":"K Paydary","year":"2016","unstructured":"Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S (2016) N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 41(2):214\u2013219","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"204_CR191","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuroimage.2008.04.233","volume":"42","author":"D Perani","year":"2008","unstructured":"Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 42(1):306\u2013314","journal-title":"NeuroImage"},{"issue":"12","key":"204_CR192","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1176\/ajp.144.12.1543","volume":"144","author":"TL Perse","year":"1987","unstructured":"Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987) Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 144(12):1543\u20131548","journal-title":"Am J Psychiatry"},{"issue":"4","key":"204_CR194","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archpsyc.59.4.381","volume":"59","author":"KA Phillips","year":"2002","unstructured":"Phillips KA, Albertini RS, Rasmussen SA (2002) A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59(4):381\u2013388","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"204_CR195","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s002130050777","volume":"140","author":"KL Pian","year":"1998","unstructured":"Pian KL, Westenberg HG, van Megen HJ, den Boer JA (1998) Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology 140(3):365\u2013370","journal-title":"Psychopharmacology"},{"key":"204_CR196","doi-asserted-by":"crossref","unstructured":"Piantadosi SC, Chamberlain BL, Glausier JR, Lewis DA, Ahmari SE (2019) Lower excitatory synaptic gene expression in orbitofrontal cortex and striatum in an initial study of subjects with obsessive compulsive disorder. Mol Psychiatry","DOI":"10.1038\/s41380-019-0431-3"},{"key":"204_CR197","first-page":"748","volume-title":"Animal models of movement disorders","author":"C Pittenger","year":"2014","unstructured":"Pittenger C (2014) Animal models of Tourette syndrome and obsessive-compulsive disorder. In: LeDoux M (ed) Animal models of movement disorders. Elsevier, Academic Press, San Deigo, pp 748\u2013766"},{"issue":"6","key":"204_CR198","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3928\/00485713-20150602-06","volume":"45","author":"C Pittenger","year":"2015","unstructured":"Pittenger C (2015) Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann 45(6):308\u2013315","journal-title":"Psychiatr Ann"},{"key":"204_CR199","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/164_2016_127","volume":"241","author":"C Pittenger","year":"2017","unstructured":"Pittenger C (2017a) Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions. Handb Exp Pharmacol 241:189\u2013215","journal-title":"Handb Exp Pharmacol"},{"key":"204_CR200","first-page":"879","volume-title":"Nestler and Charney\u2019s neurobiology of mental illness","author":"C Pittenger","year":"2017","unstructured":"Pittenger C (2017b) The neurobiology of tic disorders and obsessive-compulsive disorder: human and animal studies. In: Nestler EJ, Buxbaum JD, Sklar P, Charney DS (eds) Nestler and Charney\u2019s neurobiology of mental illness. Oxford University Press, New York, pp 879\u2013890"},{"key":"204_CR201","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780190228163.001.0001","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"C Pittenger","year":"2017","unstructured":"Pittenger C (2017c) The pharmacological treatment of refractory OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"1","key":"204_CR202","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nurx.2005.12.006","volume":"3","author":"C Pittenger","year":"2006","unstructured":"Pittenger C, Krystal JH, Coric V (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3(1):69\u201381","journal-title":"NeuroRx"},{"issue":"9","key":"204_CR203","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","volume":"22","author":"C Pittenger","year":"2008","unstructured":"Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G (2008a) Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22(9):761\u2013786","journal-title":"CNS Drugs"},{"issue":"3","key":"204_CR204","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","volume":"28","author":"C Pittenger","year":"2008","unstructured":"Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008b) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 28(3):363\u2013367","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"204_CR205","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"C Pittenger","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K (2011) Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 132(3):314\u2013332","journal-title":"Pharmacol Ther"},{"issue":"8","key":"204_CR206","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.4088\/JCP.14m09123","volume":"76","author":"C Pittenger","year":"2015","unstructured":"Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V (2015) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry 76(8):1075\u20131084","journal-title":"J Clin Psychiatry"},{"key":"204_CR207","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jad.2016.02.021","volume":"196","author":"C Pittenger","year":"2016","unstructured":"Pittenger C, Adams TG Jr, Gallezot JD, Crowley MJ, Nabulsi N, James R, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE (2016) OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. J Affect Disord 196:87\u201396","journal-title":"J Affect Disord"},{"key":"204_CR208","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780190228163.001.0001","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"C Pittenger","year":"2017","unstructured":"Pittenger C, Dulawa S, Thompson SL (2017a) Animal models of OCD: a conceptual framework. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"key":"204_CR209","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780190228163.001.0001","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"C Pittenger","year":"2017","unstructured":"Pittenger C, Gruner P, Adams TA, Kelmendi B (2017b) The dynamics of obsessive-compulsive disorder: a heuristic framework. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"12","key":"204_CR210","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0006-3223(03)00183-5","volume":"54","author":"O Pogarell","year":"2003","unstructured":"Pogarell O, Hamann C, Popperl G, Juckel G, Chouker M, Zaudig M, Riedel M, Moller HJ, Hegerl U, Tatsch K (2003) Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 54(12):1406\u20131413","journal-title":"Biol Psychiatry"},{"key":"204_CR211","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"M Poyurovsky","year":"2017","unstructured":"Poyurovsky M (2017) Obsessive-compulsive symptoms in schizophrenia. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"3","key":"204_CR212","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stampfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451\u2013457","journal-title":"Curr Biol"},{"issue":"2","key":"204_CR213","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/mp.2015.32","volume":"21","author":"H Qin","year":"2016","unstructured":"Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA, Greenberg BD, Knowles JA, Fyer AJ, McCracken JT, Murphy DL, Rasmussen SA, Cullen BA, Piacentini J, Geller D, Stewart SE, Pauls D, Bienvenu OJ, Goes FS, Maher B, Pulver AE, Valle D, Lange C, Mattheisen M, McLaughlin NC, Liang KY, Nurmi EL, Askland KD, Nestadt G, Shugart YY (2016) Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry 21(2):270\u2013276","journal-title":"Mol Psychiatry"},{"issue":"Suppl","key":"204_CR214","first-page":"10","volume":"51","author":"SA Rasmussen","year":"1990","unstructured":"Rasmussen SA, Eisen JL (1990) Epidemiology of obsessive compulsive disorder. J Clin Psychiatry 51(Suppl):10\u201313; discussion 14","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"204_CR215","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00004850-199711000-00003","volume":"12","author":"S Rasmussen","year":"1997","unstructured":"Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K (1997) A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12(6):309\u2013316","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"204_CR216","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0893-133X(02)00351-2","volume":"27","author":"SL Rauch","year":"2002","unstructured":"Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA (2002) Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27(5):782\u2013791","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"204_CR217","first-page":"368","volume":"56","author":"L Ravizza","year":"1995","unstructured":"Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995) Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 56(8):368\u2013373","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"204_CR218","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1073\/pnas.1716686115","volume":"115","author":"N Reggente","year":"2018","unstructured":"Reggente N, Moody TD, Morfini F, Sheen C, Rissman J, O'Neill J, Feusner JD (2018) Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. Proc Natl Acad Sci U S A 115(9):2222\u20132227","journal-title":"Proc Natl Acad Sci U S A"},{"key":"204_CR219","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"JE Reid","year":"2017","unstructured":"Reid JE, Reghunandanan S, Roberts A, Fineberg NA (2017) Standard evidence-based pharmacological treatment for OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"5","key":"204_CR220","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, B. and the Work Group on and a. D. o. t. A. P. A. C. o. R. Novel Treatments (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177(5):391\u2013410","journal-title":"Am J Psychiatry"},{"issue":"5","key":"204_CR221","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1101\/lm.78204","volume":"11","author":"R Richardson","year":"2004","unstructured":"Richardson R, Ledgerwood L, Cranney J (2004) Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem 11(5):510\u2013516","journal-title":"Learn Mem"},{"issue":"23","key":"204_CR222","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1001\/jama.2009.878","volume":"301","author":"N Risch","year":"2009","unstructured":"Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR (2009) Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301(23):2462\u20132471","journal-title":"JAMA"},{"issue":"10","key":"204_CR223","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1176\/ajp.139.10.1345","volume":"139","author":"N Rivers-Bulkeley","year":"1982","unstructured":"Rivers-Bulkeley N, Hollender MH (1982) Successful treatment of obsessive-compulsive disorder with loxapine. Am J Psychiatry 139(10):1345\u20131346","journal-title":"Am J Psychiatry"},{"issue":"4","key":"204_CR224","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4088\/JCP.10l06653","volume":"72","author":"CI Rodriguez","year":"2011","unstructured":"Rodriguez CI, Kegeles LS, Flood P, Simpson HB (2011) Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 72(4):567\u2013569","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"204_CR225","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38(12):2475\u20132483","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"204_CR226","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4088\/JCP.15l10318","volume":"77","author":"CI Rodriguez","year":"2016","unstructured":"Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB (2016a) Open-label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry 77(5):688\u2013689","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"204_CR227","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4088\/JCP.15l10138","volume":"77","author":"CI Rodriguez","year":"2016","unstructured":"Rodriguez CI, Wheaton M, Zwerling J, Steinman SA, Sonnenfeld D, Galfalvy H, Simpson HB (2016b) Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. J Clin Psychiatry 77(3):408\u2013409","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"204_CR228","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","volume":"39","author":"DR Rosenberg","year":"2000","unstructured":"Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39(9):1096\u20131103","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"204_CR229","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1017\/S1461145701002401","volume":"4","author":"DR Rosenberg","year":"2001","unstructured":"Rosenberg DR, MacMillan SN, Moore GJ (2001) Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder. Int J Neuropsychopharmacol 4(2):179\u2013190","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"204_CR230","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/01.chi.0000132812.44664.2d","volume":"43","author":"DR Rosenberg","year":"2004","unstructured":"Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ (2004) Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43(9):1146\u20131153","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"204_CR231","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15(1):53\u201363","journal-title":"Mol Psychiatry"},{"key":"204_CR232","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jad.2014.05.015","volume":"166","author":"A Sahraian","year":"2014","unstructured":"Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S (2014) Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. J Affect Disord 166:201\u2013205","journal-title":"J Affect Disord"},{"issue":"2","key":"204_CR233","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/JCP.0000000000000651","volume":"37","author":"A Sahraian","year":"2017","unstructured":"Sahraian A, Jahromi LR, Ghanizadeh A, Mowla A (2017) Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 37(2):246\u2013249","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"204_CR234","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/00004583-199612000-00017","volume":"35","author":"FR Sallee","year":"1996","unstructured":"Sallee FR, Richman H, Beach K, Sethuraman G, Nesbitt L (1996) Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35(12):1647\u20131656","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"204_CR235","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119592","volume":"10","author":"AS Sampaio","year":"2015","unstructured":"Sampaio AS, Hounie AG, Petribu K, Cappi C, Morais I, Vallada H, do Rosario MC, Stewart SE, Fargeness J, Mathews C, Arnold P, Hanna GL, Richter M, Kennedy J, Fontenelle L, de Braganca Pereira CA, Pauls DL, Miguel EC (2015) COMT and MAO-A polymorphisms and obsessive-compulsive disorder: a family-based association study. PLoS One 10(3):e0119592","journal-title":"PLoS One"},{"issue":"4","key":"204_CR236","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jpsychires.2009.08.007","volume":"44","author":"H Sanematsu","year":"2010","unstructured":"Sanematsu H, Nakao T, Yoshiura T, Nabeyama M, Togao O, Tomita M, Masuda Y, Nakatani E, Nakagawa A, Kanba S (2010) Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res 44(4):193\u2013200","journal-title":"J Psychiatr Res"},{"issue":"6","key":"204_CR237","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","volume":"28","author":"Y Sari","year":"2004","unstructured":"Sari Y (2004) Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev 28(6):565\u2013582","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"204_CR238","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/0976-500X.149144","volume":"6","author":"SA Sassano-Higgins","year":"2015","unstructured":"Sassano-Higgins SA, Pato MT (2015) Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: a meta-analysis. J Pharmacol Pharmacother 6(1):36\u201338","journal-title":"J Pharmacol Pharmacother"},{"issue":"6","key":"204_CR239","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0893-133X(99)00082-2","volume":"21","author":"S Saxena","year":"1999","unstructured":"Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR Jr (1999) Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21(6):683\u2013693","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"204_CR240","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1176\/appi.ajp.160.3.522","volume":"160","author":"S Saxena","year":"2003","unstructured":"Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr (2003) Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 160(3):522\u2013532","journal-title":"Am J Psychiatry"},{"key":"204_CR241","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fnbeh.2014.00338","volume":"8","author":"D Scheinost","year":"2014","unstructured":"Scheinost D, Stoica T, Wasylink S, Gruner P, Saksa J, Pittenger C, Hampson M (2014) Resting state functional connectivity predicts neurofeedback response. Front Behav Neurosci 8:338","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"204_CR242","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/157015912799362724","volume":"10","author":"F Schirmbeck","year":"2012","unstructured":"Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10(1):88\u201395","journal-title":"Curr Neuropharmacol"},{"key":"204_CR243","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2013.00099","volume":"4","author":"F Schirmbeck","year":"2013","unstructured":"Schirmbeck F, Zink M (2013) Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol 4:99","journal-title":"Front Pharmacol"},{"issue":"5","key":"204_CR244","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/YPG.0b013e328353fbee","volume":"22","author":"F Schirmbeck","year":"2012","unstructured":"Schirmbeck F, Nieratschker V, Frank J, Englisch S, Rausch F, Meyer-Lindenberg A, Rietschel M, Zink M (2012) Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents. Psychiatr Genet 22(5):245\u2013252","journal-title":"Psychiatr Genet"},{"issue":"1","key":"204_CR245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20268","volume":"25","author":"FR Schneier","year":"2008","unstructured":"Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, Laruelle M (2008) Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 25(1):1\u20137","journal-title":"Depress Anxiety"},{"issue":"2","key":"204_CR246","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hup.2461","volume":"30","author":"D Serata","year":"2015","unstructured":"Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, Piacentino D, Gasperoni C, Brugnoli R, Ferri VR, Girardi N, Tatarelli R, Ferracuti S, Angeletti G, Girardi P, Del Casale A (2015) Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol 30(2):70\u201384","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"204_CR247","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1017\/S1092852900018885","volume":"8","author":"M Serby","year":"2003","unstructured":"Serby M (2003) Methylphenidate-induced obsessive-compulsive symptoms in an elderly man. CNS Spectr 8(8):612\u2013613","journal-title":"CNS Spectr"},{"issue":"5","key":"204_CR250","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.biopsych.2008.09.026","volume":"65","author":"NA Shanahan","year":"2009","unstructured":"Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC (2009) Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry 65(5):401\u2013408","journal-title":"Biol Psychiatry"},{"key":"204_CR251","doi-asserted-by":"publisher","first-page":"102183","DOI":"10.1016\/j.ajp.2020.102183","volume":"52","author":"LP Sharma","year":"2020","unstructured":"Sharma LP, Thamby A, Balachander S, Janardhanan CN, Jaisoorya TS, Arumugham SS, Reddy YCJ (2020) Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian J Psychiatr 52:102183","journal-title":"Asian J Psychiatr"},{"issue":"8","key":"204_CR252","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.biopsych.2013.09.002","volume":"75","author":"DJ Shin","year":"2014","unstructured":"Shin DJ, Jung WH, He Y, Wang J, Shim G, Byun MS, Jang JH, Kim SN, Lee TY, Park HY, Kwon JS (2014) The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry 75(8):606\u2013614","journal-title":"Biol Psychiatry"},{"issue":"5","key":"204_CR253","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nm.2125","volume":"16","author":"SV Shmelkov","year":"2010","unstructured":"Shmelkov SV, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T, Shmelkov E, Kushner JS, Baljevic M, Dincheva I, Murphy AJ, Valenzuela DM, Gale NW, Yancopoulos GD, Ninan I, Lee FS, Rafii S (2010) Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 16(5):598\u2013602, 591p following 602","journal-title":"Nat Med"},{"issue":"12","key":"204_CR254","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0006-3223(03)00544-4","volume":"54","author":"HB Simpson","year":"2003","unstructured":"Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, Liebowitz MR, Laruelle M (2003) Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry 54(12):1414\u20131421","journal-title":"Biol Psychiatry"},{"issue":"9","key":"204_CR255","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.biopsych.2011.06.023","volume":"70","author":"HB Simpson","year":"2011","unstructured":"Simpson HB, Slifstein M, Bender J Jr, Xu X, Hackett E, Maher MJ, Abi-Dargham A (2011) Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907. Biol Psychiatry 70(9):897\u2013904","journal-title":"Biol Psychiatry"},{"issue":"12","key":"204_CR256","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1038\/npp.2012.132","volume":"37","author":"HB Simpson","year":"2012","unstructured":"Simpson HB, Shungu DC, Bender J Jr, Mao X, Xu X, Slifstein M, Kegeles LS (2012) Investigation of cortical glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology 37(12):2684\u20132692","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"204_CR257","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","volume":"70","author":"HB Simpson","year":"2013","unstructured":"Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R (2013) Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiat 70(11):1190\u20131199","journal-title":"JAMA Psychiat"},{"key":"204_CR258","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.neubiorev.2017.05.029","volume":"80","author":"VM Sinopoli","year":"2017","unstructured":"Sinopoli VM, Burton CL, Kronenberg S, Arnold PD (2017) A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev 80:372\u2013381","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"204_CR259","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","volume":"17","author":"P Skapinakis","year":"2007","unstructured":"Skapinakis P, Papatheodorou T, Mavreas V (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17(2):79\u201393","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"204_CR260","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","volume":"3","author":"P Skapinakis","year":"2016","unstructured":"Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G (2016) Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 3(8):730\u2013739","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"204_CR261","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/0006-3223(95)00393-2","volume":"40","author":"E Smeraldi","year":"1996","unstructured":"Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, Bellodi L, Moja EA (1996) Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 40(5):398\u2013402","journal-title":"Biol Psychiatry"},{"key":"204_CR262","volume":"1","author":"GM Soomro","year":"2008","unstructured":"Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008) Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 1:CD001765","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"204_CR263","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1590\/S1516-44462007000400003","volume":"29","author":"DJ Stein","year":"2007","unstructured":"Stein DJ, Andersen EW, Overo KF (2007) Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Braz J Psychiatry 29(4):303\u2013307","journal-title":"Braz J Psychiatry"},{"issue":"2","key":"204_CR264","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41386-018-0174-x","volume":"44","author":"ER Stern","year":"2019","unstructured":"Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, Parides MK, Coffey BJ, Burdick KE, Goodman WK (2019) High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology 44(2):390\u2013398","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"204_CR265","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","volume":"30","author":"SE Stewart","year":"2010","unstructured":"Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA (2010) A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 30(1):34\u201339","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"204_CR266","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajmg.b.32137","volume":"162B","author":"SE Stewart","year":"2013","unstructured":"Stewart SE, Mayerfeld C, Arnold PD, Crane JR, O'Dushlaine C, Fagerness JA, Yu D, Scharf JM, Chan E, Kassam F, Moya PR, Wendland JR, Delorme R, Richter MA, Kennedy JL, Veenstra-VanderWeele J, Samuels J, Greenberg BD, McCracken JT, Knowles JA, Fyer AJ, Rauch SL, Riddle MA, Grados MA, Bienvenu OJ, Cullen B, Wang Y, Shugart YY, Piacentini J, Rasmussen S, Nestadt G, Murphy DL, Jenike MA, Cook EH, Pauls DL, Hanna GL, Mathews CA (2013a) Meta-analysis of association between obsessive-compulsive disorder and the 3\u2032 region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet 162B(4):367\u2013379","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"7","key":"204_CR267","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/mp.2012.85","volume":"18","author":"SE Stewart","year":"2013","unstructured":"Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, Arnold PD, Evans PD, Gamazon ER, Davis LK, Osiecki L, McGrath L, Haddad S, Crane J, Hezel D, Illman C, Mayerfeld C, Konkashbaev A, Liu C, Pluzhnikov A, Tikhomirov A, Edlund CK, Rauch SL, Moessner R, Falkai P, Maier W, Ruhrmann S, Grabe HJ, Lennertz L, Wagner M, Bellodi L, Cavallini MC, Richter MA, Cook EH Jr, Kennedy JL, Rosenberg D, Stein DJ, Hemmings SM, Lochner C, Azzam A, Chavira DA, Fournier E, Garrido H, Sheppard B, Umana P, Murphy DL, Wendland JR, Veenstra-VanderWeele J, Denys D, Blom R, Deforce D, Van Nieuwerburgh F, Westenberg HG, Walitza S, Egberts K, Renner T, Miguel EC, Cappi C, Hounie AG, do Rosario MC, Sampaio AS, Vallada H, Nicolini H, Lanzagorta N, Camarena B, Delorme R, Leboyer M, Pato CN, Pato MT, Voyiaziakis E, Heutink P, Cath DC, Posthuma D, Smit JH, Samuels J, Bienvenu OJ, Cullen B, Fyer AJ, Grados MA, Greenberg BD, McCracken JT, Riddle MA, Wang Y, Coric V, Leckman JF, Bloch M, Pittenger C, Eapen V, Black DW, Ophoff RA, Strengman E, Cusi D, Turiel M, Frau F, Macciardi F, Gibbs JR, Cookson MR, Singleton A, C. North American Brain Expression, Hardy J, U. K. B. E. Database, Crenshaw AT, Parkin MA, Mirel DB, Conti DV, Purcell S, Nestadt G, Hanna GL, Jenike MA, Knowles JA, Cox N, Pauls DL (2013b) Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry 18(7):788\u2013798","journal-title":"Mol Psychiatry"},{"issue":"7","key":"204_CR268","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/da.20197","volume":"23","author":"EA Storch","year":"2006","unstructured":"Storch EA, Larson MJ, Shapira NA, Ward HE, Murphy TK, Geffken GR, Valerio H, Goodman WK (2006) Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety 23(7):429\u2013433","journal-title":"Depress Anxiety"},{"issue":"6","key":"204_CR269","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archpsyc.1989.01810060038007","volume":"46","author":"SE Swedo","year":"1989","unstructured":"Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL (1989) Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 46(6):518\u2013523","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"204_CR270","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/archpsyc.1992.01820090018003","volume":"49","author":"SE Swedo","year":"1992","unstructured":"Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL (1992) Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry 49(9):690\u2013694","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"204_CR271","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1037\/0735-7044.112.6.1475","volume":"112","author":"H Szechtman","year":"1998","unstructured":"Szechtman H, Sulis W, Eilam D (1998) Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112(6):1475\u20131485","journal-title":"Behav Neurosci"},{"issue":"Pt B","key":"204_CR272","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neubiorev.2016.04.019","volume":"76","author":"H Szechtman","year":"2017","unstructured":"Szechtman H, Ahmari SE, Beninger RJ, Eilam D, Harvey BH, Edemann-Callesen H, Winter C (2017) Obsessive-compulsive disorder: Insights from animal models. Neurosci Biobehav Rev 76(Pt B):254\u2013279","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"204_CR273","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/pr.119.017772","volume":"72","author":"H Szechtman","year":"2020","unstructured":"Szechtman H, Harvey BH, Woody EZ, Hoffman KL (2020) The psychopharmacology of obsessive-compulsive disorder: a preclinical roadmap. Pharmacol Rev 72(1):80\u2013151","journal-title":"Pharmacol Rev"},{"key":"204_CR274","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.psychres.2017.03.033","volume":"253","author":"A Talati","year":"2017","unstructured":"Talati A, Odgerel Z, Wickramaratne PJ, Norcini-Pala A, Skipper JL, Gingrich JA, Weissman MM (2017) Associations between serotonin transporter and behavioral traits and diagnoses related to anxiety. Psychiatry Res 253:211\u2013219","journal-title":"Psychiatry Res"},{"issue":"7","key":"204_CR275","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/mp.2012.76","volume":"18","author":"S Taylor","year":"2013","unstructured":"Taylor S (2013) Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol Psychiatry 18(7):799\u2013805","journal-title":"Mol Psychiatry"},{"issue":"3","key":"204_CR276","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajmg.b.32407","volume":"171B","author":"S Taylor","year":"2016","unstructured":"Taylor S (2016) Disorder-specific genetic factors in obsessive-compulsive disorder: a comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet 171B(3):325\u2013332","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"204_CR277","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1875397300802010062","volume":"2","author":"JT Ting","year":"2008","unstructured":"Ting JT, Feng G (2008) Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genom 2:62\u201375","journal-title":"Curr Chem Genom"},{"key":"204_CR278","volume-title":"Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment","author":"AR Torres","year":"2017","unstructured":"Torres AR, Fontenelle LH, Shhavitt RG, Hoexter MQ, Pittenger C, Miguel EC (2017) Epidemiology, comorbidity, and burden of OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York"},{"issue":"6868","key":"204_CR279","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(55)90483-9","volume":"268","author":"WH Trethowan","year":"1955","unstructured":"Trethowan WH, Scott PA (1955) Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 268(6868):781\u2013785","journal-title":"Lancet"},{"issue":"3","key":"204_CR280","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1177\/0269881108098809","volume":"24","author":"O Uzun","year":"2010","unstructured":"Uzun O (2010) Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 24(3):425\u2013427","journal-title":"J Psychopharmacol"},{"issue":"1","key":"204_CR281","doi-asserted-by":"publisher","first-page":"17464","DOI":"10.1038\/s41598-017-17593-7","volume":"7","author":"AL van der Straten","year":"2017","unstructured":"van der Straten AL, Denys D, van Wingen GA (2017) Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis. Sci Rep 7(1):17464","journal-title":"Sci Rep"},{"issue":"12","key":"204_CR282","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1176\/appi.ajp.161.12.2201","volume":"161","author":"NJ van der Wee","year":"2004","unstructured":"van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, Kahn RS, Westenberg HM (2004) Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry 161(12):2201\u20132206","journal-title":"Am J Psychiatry"},{"issue":"4","key":"204_CR283","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0091-3057(96)00321-8","volume":"57","author":"I Vandebroek","year":"1997","unstructured":"Vandebroek I, Odberg FO (1997) Effect of apomorphine on the conflict-induced jumping stereotypy in bank voles. Pharmacol Biochem Behav 57(4):863\u2013868","journal-title":"Pharmacol Biochem Behav"},{"key":"204_CR284","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","volume":"14","author":"D Veale","year":"2014","unstructured":"Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (2014) Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 14:317","journal-title":"BMC Psychiatry"},{"issue":"2","key":"204_CR285","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4088\/JCP.v66n0211","volume":"66","author":"NC Vulink","year":"2005","unstructured":"Vulink NC, Denys D, Westenberg HG (2005) Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 66(2):228\u2013230","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"204_CR286","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0006-3223(92)90280-D","volume":"31","author":"A Weizman","year":"1992","unstructured":"Weizman A, Mandel A, Barber Y, Weitz R, Cohen A, Mester R, Rehavi M (1992) Decreased platelet imipramine binding in Tourette syndrome children with obsessive-compulsive disorder. Biol Psychiatry 31(7):705\u2013711","journal-title":"Biol Psychiatry"},{"issue":"7156","key":"204_CR287","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature06104","volume":"448","author":"JM Welch","year":"2007","unstructured":"Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, Dudek SM, Weinberg RJ, Calakos N, Wetsel WC, Feng G (2007) Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448(7156):894\u2013900","journal-title":"Nature"},{"issue":"4","key":"204_CR288","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archgenpsychiatry.2009.6","volume":"66","author":"JR Wendland","year":"2009","unstructured":"Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL (2009) A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 66(4):408\u2013416","journal-title":"Arch Gen Psychiatry"},{"key":"204_CR289","volume-title":"Tourette syndrome. Neurobiology of mental illness","author":"K Williams","year":"2013","unstructured":"Williams K, Bloch MH, State MW, Pittenger C (2013) In: Buxbaum JD, Sklar P, Nestler EJ et al (eds) Tourette syndrome. Neurobiology of mental illness, 4th edn. Oxford University Press, New York","edition":"4"},{"issue":"3","key":"204_CR290","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1086\/423899","volume":"75","author":"VL Willour","year":"2004","unstructured":"Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu OJ 3rd, Wang Y, Liang KY, Valle D, Hoehn-Saric R, Riddle M, Nestadt G (2004) Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet 75(3):508\u2013513","journal-title":"Am J Hum Genet"},{"issue":"D1","key":"204_CR291","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074\u2013D1082","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"204_CR292","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00213-013-2985-0","volume":"227","author":"NS Woehrle","year":"2013","unstructured":"Woehrle NS, Klenotich SJ, Jamnia N, Ho EV, Dulawa SC (2013) Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation. Psychopharmacology 227(3):545\u2013551","journal-title":"Psychopharmacology"},{"issue":"1","key":"204_CR293","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1176\/appi.ajp.160.1.183","volume":"160","author":"JB Woolley","year":"2003","unstructured":"Woolley JB, Heyman I (2003) Dexamphetamine for obsessive-compulsive disorder. Am J Psychiatry 160(1):183","journal-title":"Am J Psychiatry"},{"issue":"3","key":"204_CR294","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/JCP.0b013e3182189878","volume":"31","author":"PL Wu","year":"2011","unstructured":"Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE (2011) Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol 31(3):369\u2013374","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"204_CR295","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JCP.0000000000000362","volume":"35","author":"KU Yazici","year":"2015","unstructured":"Yazici KU, Percinel I (2015) N-Acetylcysteine augmentation in children and adolescents diagnosed with treatment-resistant obsessive-compulsive disorder: case series. J Clin Psychopharmacol 35(4):486\u2013489","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"204_CR296","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.biopsych.2018.04.006","volume":"84","author":"D Yin","year":"2018","unstructured":"Yin D, Zhang C, Lv Q, Chen X, Zeljic K, Gong H, Zhan S, Jin H, Wang Z, Sun B (2018) Dissociable frontostriatal connectivity: mechanism and predictor of the clinical efficacy of capsulotomy in obsessive-compulsive disorder. Biol Psychiatry 84(12):926\u2013936","journal-title":"Biol Psychiatry"},{"issue":"3","key":"204_CR297","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1440-1819.2006.01519.x","volume":"60","author":"R Yoshimura","year":"2006","unstructured":"Yoshimura R, Kaneko S, Shinkai K, Nakamura J (2006) Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 60(3):389\u2013393","journal-title":"Psychiatry Clin Neurosci"},{"key":"204_CR298","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pnpbp.2015.06.009","volume":"63","author":"JY Yun","year":"2015","unstructured":"Yun JY, Jang JH, Kim SN, Jung WH, Kwon JS (2015) Neural correlates of response to pharmacotherapy in obsessive-compulsive disorder: individualized cortical morphology-based structural covariance. Prog Neuro-Psychopharmacol Biol Psychiatry 63:126\u2013133","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"8","key":"204_CR299","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/pgs.14.83","volume":"15","author":"G Zai","year":"2014","unstructured":"Zai G, Brandl EJ, Muller DJ, Richter MA, Kennedy JL (2014) Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics 15(8):1147\u20131157","journal-title":"Pharmacogenomics"},{"issue":"8","key":"204_CR300","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856\u2013864","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"204_CR301","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.euroneuro.2018.12.010","volume":"29","author":"H Zheng","year":"2019","unstructured":"Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H (2019) Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study. Eur Neuropsychopharmacol 29(3):397\u2013404","journal-title":"Eur Neuropsychopharmacol"},{"issue":"22","key":"204_CR302","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1073\/pnas.1701736114","volume":"114","author":"ID Zike","year":"2017","unstructured":"Zike ID, Chohan MO, Kopelman JM, Krasnow EN, Flicker D, Nautiyal KM, Bubser M, Kellendonk C, Jones CK, Stanwood G, Tanaka KF, Moore H, Ahmari SE, Veenstra-VanderWeele J (2017) OCD candidate gene SLC1A1\/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci U S A 114(22):5719\u20135724","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"204_CR303","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","volume":"170","author":"K Zivin","year":"2013","unstructured":"Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC (2013) Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 170(6):642\u2013650","journal-title":"Am J Psychiatry"},{"issue":"Suppl 14","key":"204_CR304","first-page":"18","volume":"65","author":"J Zohar","year":"2004","unstructured":"Zohar J, Kennedy JL, Hollander E, Koran LM (2004) Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry 65(Suppl 14):18\u201321","journal-title":"J Clin Psychiatry"}],"container-title":["Current Topics in Behavioral Neurosciences","The Neurobiology and Treatment of OCD: Accelerating Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2020_204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T21:59:37Z","timestamp":1671573577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2020_204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030753924","9783030753931"],"references-count":303,"URL":"https:\/\/doi.org\/10.1007\/7854_2020_204","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"10 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}